Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00997022 · ClinicalTrials.gov registry record · Phase 1
Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients
A Phase 1 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00997022 is a Phase 1 study that has completed, run by Columbia University. The registered enrollment target is 14 participants.
The verdict
NCT00997022, a Phase 1 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This Phase I study of sorafenib in high risk hepatocellular cancer patients after liver transplantation will study 24 subjects for about 5 years. Each subject will receive sorafenib for 6 months. Safety and effectiveness on the post transplant, high risk HCC patients will be studied.
Interventions
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2009-05 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00997022
The ClinicalTrials.gov registry entry for NCT00997022 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib is the first listed.
NCT00997022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00997022 about?
NCT00997022 is a clinical study titled "Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients". This Phase I study of sorafenib in high risk hepatocellular cancer patients after liver transplantation will study 24 subjects for about 5 years. Each subject will receive sorafenib for 6 months. Safety and effectiveness on the post transplant, high risk HCC patients will be studied.
What is the current status of trial NCT00997022?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2009-05. Estimated completion is 2015-05.
What interventions are being tested in trial NCT00997022?
The interventions under investigation include: Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00997022?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.